| Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase … D Marin, AR Ibrahim, C Lucas, G Gerrard, L Wang, RM Szydlo, RE Clark, ... Journal of Clinical Oncology 30 (3), 232, 2012 | 590 | 2012 |
| Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression CM Lucas, RJ Harris, A Giannoudis, M Copland, JR Slupsky, RE Clark Blood, The Journal of the American Society of Hematology 117 (24), 6660-6668, 2011 | 176 | 2011 |
| Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia A Giannoudis, A Davies, CM Lucas, RJ Harris, M Pirmohamed, RE Clark Blood, The Journal of the American Society of Hematology 112 (8), 3348-3354, 2008 | 171 | 2008 |
| Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript CM Lucas, RJ Harris, A Giannoudis, A Davies, K Knight, SJ Watmough, ... haematologica 94 (10), 1362, 2009 | 164 | 2009 |
| A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials CM Lucas, L Wang, GM Austin, K Knight, SJ Watmough, KH Shwe, ... Leukemia 22 (10), 1963-1966, 2008 | 133 | 2008 |
| Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters A Davies, NE Jordanides, A Giannoudis, CM Lucas, S Hatziieremia, ... Leukemia 23 (11), 1999-2006, 2009 | 125 | 2009 |
| Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies P Neelakantan, G Gerrard, C Lucas, D Milojkovic, P May, L Wang, ... Blood, The Journal of the American Society of Hematology 121 (14), 2739-2742, 2013 | 113 | 2013 |
| The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia L Wang, K Knight, C Lucas, RE Clark Haematologica 91 (2), 235-239, 2006 | 80 | 2006 |
| Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients CM Lucas, RJ Harris, AK Holcroft, LJ Scott, N Carmell, E McDonald, ... Leukemia 29 (7), 1514-1523, 2015 | 40 | 2015 |
| High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia CM Lucas, M Milani, M Butterworth, N Carmell, LJ Scott, RE Clark, ... Leukemia 30 (6), 1273-1281, 2016 | 35 | 2016 |
| The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia A Giannoudis, A Davies, RJ Harris, CM Lucas, M Pirmohamed, RE Clark Leukemia 28 (6), 1360-1363, 2014 | 27 | 2014 |
| BCR‐ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia CM Lucas, RJ Harris, A Giannoudis, K Knight, SJ Watmough, RE Clark British journal of haematology 149 (3), 458-460, 2010 | 26 | 2010 |
| Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia CM Lucas, RJ Harris, A Giannoudis, E McDonald, RE Clark haematologica 99 (11), 1710, 2014 | 23 | 2014 |
| c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia CM Lucas, RJ Harris, A Giannoudis, RE Clark Haematologica 100 (5), e179, 2015 | 20 | 2015 |
| CIP2A-and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML CM Lucas, LJ Scott, N Carmell, AK Holcroft, RK Hills, AK Burnett, ... Blood Advances 2 (9), 964-968, 2018 | 19 | 2018 |
| A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia S Francis, C Lucas, S Lane, L Wang, S Watmough, K Knight, J Bell, ... Leukemia research 37 (7), 752-758, 2013 | 18 | 2013 |
| Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias E Mäkelä, K Pavic, T Varila, U Salmenniemi, E Löyttyniemi, SG Nagelli, ... Clinical Cancer Research 27 (10), 2848-2860, 2021 | 14 | 2021 |
| Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors? HH Saifullah, CM Lucas Cancers 13 (16), 4175, 2021 | 11 | 2021 |
| Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia” D Perrotti, A Agarwal, CM Lucas, G Narla, P Neviani, MD Odero, ... Science translational medicine 11 (501), eaau0416, 2019 | 9 | 2019 |
| Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein CM Lucas, JL Fagan, A Carter, B Swale, C Evans, RE Clark, RJ Harris haematologica 96 (7), 1077, 2011 | 8 | 2011 |
